Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK

OBJECTIVES: Budesonide/formoterol (BF) Spiromax(®) is an inhaled corticosteroid/long-acting β(2)-agonist fixed-dose combination (FDC) inhaler, designed to minimise common inhaler errors and provide reliable and consistent dose delivery in asthma and chronic obstructive pulmonary disease (COPD). We e...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMJ Open
Hlavní autoři: Voorham, Jaco, Roche, Nicolas, Benhaddi, Hicham, van der Tol, Marianka, Carter, Victoria, van Boven, Job F.M., Bjermer, Leif, Miravitlles, Marc, Price, David B
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2018
Témata:
Respiratory Medicine
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6224753/
https://ncbi.nlm.nih.gov/pubmed/30368448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2018-022051
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky